RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company continues to drive steady advancement of its diverse pipeline in the background, but attention remains squarely on the RRP opportunity, commercial setup, and Inovio’s ability to execute, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the one-year cash runway for 3107’s critical though risky path.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio Pharmaceuticals: Hold Rating Amid Promising Developments and Financial Challenges
- Inovio price target lowered to $12 from $18 at Citizens JMP
- Inovio Pharmaceuticals Reports 2024 Financial Results
- Inovio reports Q4 EPS (65c), consensus (83c)
- Inovio options imply 8.1% move in share price post-earnings
Questions or Comments about the article? Write to editor@tipranks.com